MedTrace Logo

The Effect of Ribose on B-Type Natriuretic Peptide (BNP) Levels in Congestive Heart Failure Patients

NCT00329485 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2007-08-02

No results posted yet for this study

Summary

The purpose of this research study is to test the effectiveness of CORvalen, a medical food, to increase cellular energy sufficiently to change or modify BNP levels in congestive heart failure patients.

Conditions

  • Congestive Heart Failure

Interventions

DRUG

CORvalen (D-Ribose)

Sponsors & Collaborators

  • Valen Labs

    lead INDUSTRY

Principal Investigators

  • Garrie Haas, MD · Ohio State University

  • Mark Munger, PharmD · University of Utah

  • Reynolds Delgado, MD · Texas Heart Institute

  • Daniel Pauly, MD, PhD · University of Florida

  • Kris Vijay, MD · Scottsdale Cardiovascular Research Institute

  • Masoor Kamalesh, MD · Roudebush VA Medical Center

  • Robert J Weiss, MD · Maine Research Associates

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Completion
2007-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00329485 on ClinicalTrials.gov